key: cord-0930372-5goaotx2
authors: Rai, Deependra Kumar
title: Effectiveness of remdesivir on hospital stay duration and mortality in patients with COVID-19 infection: A single-center retrospective observational study
date: 2021-12-28
journal: Lung India
DOI: 10.4103/lungindia.lungindia_268_21
sha: 0bd3aa8882fc57e885d9eae623190ea6d426a225
doc_id: 930372
cord_uid: 5goaotx2

nan

Sir, Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) was first time detected in December 2019 in Wuhan, China. [1] It is responsible for COVID-19 infection, a global pandemic affecting millions of populations worldwide including health-care workers with a mortality of 16% in an intensive care unit (ICU) from western India. [2] The clinical spectrum of SARS-CoV-2 infection ranges from asymptomatic or mild, self-limited respiratory tract disease to severe progressive pneumonia leading to acute respiratory distress syndrome and death due to multi-organ failure. At the beginning of the epidemic, only supportive care was available, but the rapid worldwide spread of COVID-19 has raised a desperate need to invent Continuous data were presented as mean ± standard deviation and categorical variables in relative frequencies and percentages. All statistical analyses were performed using SPSS version 21.0 (SPSS Inc., Chicago, IL, USA). Comparisons were determined by t-test or Mann-Whitney U-test for continuous variables, as appropriate, and Chi-squared test or Fisher exact test for categorical variables. The statistical significance level was set at 0.05 (two-tailed).

Among 964 patients included in the study, 731 (75.82%) patients suffered from mild-to-moderate infection while 233 (24.17%) from severe COVID-19 infection at the time of admission. Remdesivir received by 226 patients (23.44%). Baseline characteristics of remdesivir and nonremsdesivir group are summarized in Table 1 . There was significantly higher proportion of elderly patients who received remdesivir (49.11% vs. 24.79%, P < 0.05). Remdesivir was prescribed more frequently in severe patients compared to mild-moderate disease (48.92 vs. 15.32%) [ Figure 1 ]. There was significantly higher mortality in remdesivir group (50.44% vs. 16.12%, P < 0.05). The prevalence of comorbidities such as diabetes, hypertension, and chronic obstructive airway disease was significantly higher among patients treated with remdesivir (P < 0.05). Remdesivir group received additional medication such as dexamethasone, convalescent plasma, and tocilizumab more frequently than nonremdesivir group, while hydroxychloroquine prescribed more in the latter group (P < 0.05). Proportion of patients who require O 2 inhalation, intensive care requirement (ICU), noninvasive ventilation (NIV), and mechanical ventilation were significantly higher in remdesivir group [ Table 1 ]. Remdesivir group showed higher mortality in comparison to nonremdesivir group for both mild-moderate disease (20.53% versus 10.1%) and severe disease (78.07% versus 63.86%) [ Figure 1 ]. Patients with additional treatment such as O 2 inhalation, hydroxychloroquine, injection dexona, NIV, and mechanical ventilation do not associated with a reduction in mortality [ Table 2 ]. The hospital stay duration was slightly higher in remdesivir group but statistically not significant (12.12 ± 5.90 days vs. 9.47 ± 5.88, P > 0.05). FDA approval for remdesivir was based largely on the results of Adaptive COVID-19 Treatment Trial-1 in hospitalized patients with disease of varying severity. [6] They found that recovery was faster mainly in patients who require low flow oxygen with no difference in mortality. Later on, this drug was approved in India and other countries, especially for patients with low blood oxygen saturation. However, there is no specific guideline for its specific indication and used across wide severity of COVID-19 disease. Our finding showed that remdesivir does not reduce hospital stay duration or mortality in any severity of COVID-19 infection. The strong part of the study was a large cohort of patients and the first of such study in this region to look on the effect of remdesivir on mortality and its effect on hospital stay duration. The major limitation of the study was retrospectives design which is associated with selection bias. As both remdesivir and nonremdesivir group are not matched, other confounder may affect the outcome. There an antiviral agent active against SARS-CoV-2. There are several antiviral agents such as remdesivir, ritonavir/ lopinavir, and their combination, and immunomodulating therapies such as tocilizumab, convalescent plasma, and interferon are currently being evaluated in randomized controlled trials in many countries to evaluate their efficacy and safety in the treatment of COVID-19. Remdesivir was considered as a potential candidate drug for the treatment of COVID-19. Recent studies have shown promising results and have been regarded as a "molecule of hope" for the treatment of COVID-19. [3] On October 22, 2020, remdesivir became the first United States Food and Drug Administration (FDA) approved drug for the treatment of hospitalized COVID-19 patients. [4] The purpose of the retrospective study was to evaluate the effect of remdesivir on hospital stay duration and mortality in patients who hospitalized with COVID-19 infection All the patients admitted with RTPCR-or Antigen positive COVID-19 infection between July 01, 2020, and August 31, 2020, were included in the study. Institutional Human Ethics Committee of AIIMS Patna reviewed and approved the study protocol with approval letter number (AIIMS/ Pat/IEC/220/552). All the admitted patients were investigated and treated with standard drugs according to the standard operating procedure of institute. The data we retrieved from the medical records department included demographic information, recent exposure history, clinical symptoms, comorbidity, laboratory test results, diagnostic classification, treatment, length of hospitalization, complication, and outcome. All the data was checked by two physicians. The severity of COVID-19 infection was classified according to the Ministry of Health and Family Welfare guidelines. [5] Remdesivir was administered intravenously at a loading dose of 200 mg once a day and later at a maintenance dose of 100 mg for 4 days. There were no specific inclusion criteria to give remdesivir but rather given on physician discretion or availability of the drug. It is mostly given to a patient with moderate-to-severe COVID infection with normal hepatorenal function. The outcome variable measured was as 1. Proportion of patient died in remdesivir and nonremdesivir group 2. Effect of remdesivir on hospital stay duration.

Definitions of mild, moderate, and severe COVID-19 [5] • Mild: No evidence of breathlessness or hypoxia (normal saturation) • Moderate: Breathlessness and/or hypoxia (saturation 90%-94% on room air), respiratory rate of 24 or more, and no features of severe disease • Severe: Any of the following -severe respiratory distress, oxygen saturation <90% on room air, respiratory rate >30, shock, or evidence of a life-threatening organ dysfunction. were more elderly group in remdesivir group; similarly, other treatments were different in both the groups which could be a cause for the difference in mortality and hospital stay duration.

Remdesivir administration is not associated with a reduction in hospital stay duration or mortality either mild-to-moderate COVID-19 infection or severe COVID-19 infection.

Nil.

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72 314 cases from the Chinese center for disease control and prevention

Initial experience of critically ill patients with COVID-19 in Western India: A case series

Probable molecular mechanism of remdesivir for the treatment of COVID-19: Need to know more

Ministry of Health and Family Welfare (Government of India)

Remdesivir for the treatment of COVID-19 -Final report